Engineered immune cells target root cause of debilitating neurological disease
NCT ID NCT06588491
Summary
This study is testing whether a therapy called KYV-101 can help people with Stiff Person Syndrome (SPS) who haven't improved with other treatments. KYV-101 uses a patient's own immune cells, which are modified in a lab to find and remove the specific B cells thought to drive the disease. The goal is to see if this one-time treatment can reduce stiffness, improve walking, and slow or stop disease progression for the 25 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STIFF PERSON SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.